Cerecin Inc.
44 Cook Street
Suite 100-71
Denver
Colorado
80206
United States
Tel: 303-999-3700
Website: http://www.cerecin.com/
56 articles about Cerecin Inc.
-
Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.
12/1/2023
Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding with A*STAR's Institute of Molecular and Cell Biology.
-
Cerecin strengthens position in neurometabolism with addition to pipeline
9/19/2023
Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, announced the in-license of CER-022 from the University of Alberta.
-
Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023
8/29/2023
Cerecin Inc. announced that new data on investigational CER-0001 in infantile spasms has been accepted for presentation at the 35th International Epilepsy Congress, held in Dublin, Ireland from September 2nd-6th 2023.
-
Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent
6/30/2023
Cerecin Inc. presented encouraging findings from a recent study on CER-0001, an investigational ketogenic agent, indicating that certain individuals suffering from migraines may experience benefit.
-
The Biotechnology Innovation Organization, Passage Bio and Palisade Bio saw leadership shakeups at the top, while Maze Therapeutics, Cerecin and more appointed new chief medical officers.
-
Cerecin appoints biotech veteran Joseph S. Zakrzewski as its new Chairman
12/20/2019
Cerecin, an innovative biopharmaceutical company focused on brain health, announced that Joseph S. Zakrzewski has joined the Company’s Board of Directors as Chairman.
-
Cerecin strengthens its leadership position in CNS drug development by adding a biotech veteran to the executive team
11/4/2019
Bruce Morimoto joins Cerecin as Vice President of Drug Development
-
Lilian Chow joins Cerecin as Vice President of Clinical Operations and Regulatory Affairs
10/7/2019
Cerecin continues to strengthen its experienced team in Asia Pacific as it accelerates clinical development plans
-
With the latest major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease.
-
Accera closes new investment led by Asia's leading agribusiness group, Wilmar, and rebrands as Cerecin
10/4/2018
Cerecin announces first close of a new investment round and establishment of new global HQ in Singapore
-
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
9/28/2018
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.
-
Accera Enters Into A Strategic Partnership And Exclusive Licensing Agreement With DuChemBio For Accera's Technology In Korea
7/11/2017
-
Accera Appoints Dr. Judith Walker As Chief Medical Officer
5/3/2017
-
Frustration Sets In as Accera's Alzheimer's Drug Flunks Late-Stage Trial
2/28/2017
-
Accera, Inc. To Present At Upcoming Healthcare And Investor Conferences
9/26/2016
-
Accera, Inc. Appoints Jeffrey Cummings And Bruno Vellas To Scientific Advisory Board
9/8/2016
-
Accera, Inc. Appoints C. Evan Ballantyne As Chief Financial Officer
8/2/2016
-
Accera, Inc. To Present At The JMP Securities Life Science Conference
6/17/2016
-
Accera, Inc. Completes Enrollment Of Phase 3 NOURISH AD Study Of AC-1204 For The Treatment Of Alzheimer's Disease
5/12/2016
-
Accera, Inc. To Present At BIO Asia International Conference
3/14/2016